Clinical trials
catalyst calendar across sponsors →Studies where CGON is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 expanded access
Held by 8 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., Man Group plc, Balyasny Asset Management L.P., SUSQUEHANNA INTERNATIONAL GROUP, LLP, +3 more) · FINRA short interest 13.5 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinNCT04452591Cohort C:Non-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Biological: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | 190 | 2030-06-16 | in 1,397 d | 2026-07-10 |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCNCT06567743Cohort A (Arm 1 and 2): Complete response rateRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Cretostimogene Grenadenorepvec | High-Risk Non-Muscle-Invasive Bladder Cancer | 325 | 2027-03-31 | in 224 d | 2026-04-08 |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235Recurrence Free Survival (RFS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | 367 | Nov 2026 | ≤ 103 d | 2026-07-01 |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461Complete response rate in patientsOpen-label · Treatment | Phase 2 | Completed | Biological: CG0070, Pembrolizumab Injection · Other: n-dodecyl-B-D-maltoside | Non Muscle Invasive Bladder Cancer | 35 | 2023-03-07actual | — | 2024-09-25 |
| Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG FailureNCT02365818Durable Complete Response Proportion (DCR)Open-label · Treatment | Phase 2 | Completed | Biological: CG0070 | Bladder Cancer | 66 | Aug 2018actual | — | 2021-04-14 |
| Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerNCT01438112Complete Response Proportion (CR)Randomized · Open-label · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: Change in study design | Biological: CG0070 Adenovirus Vector · Other: Control Arm: Quadruple Choice | Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors | 22 | Jun 2016actual | — | 2021-04-14 |
| Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerNCT02143804Durable Complete Response ProportionOpen-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Change in trial design | Biological: oncolytic adenovirus expressing GMCSF | Bladder Cancer, High Grade, Non Muscle Invasive | 0 | Mar 2015actual | — | 2026-04-02 |
| An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGNCT06443944expanded access | — | Available | Drug: Cretostimogene Grenadenorepvec · Other: n-dodecyl-B-D-maltoside | Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Bladder Cancer | — | — | — | 2026-04-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19